CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cellsTobias Bexte, Evelyn Ullrich, Beate Anahita Jung et al.|Nature Communications|2024Cited by 71
Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53Patrizia Malkomes, Michael A. Rieger|Oncogene|2021Cited by 40
Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem CellsPatrizia Malkomes, Michael A. Rieger|Annals of Surgical Oncology|2016Cited by 33
CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AMLNawid Albinger, Evelyn Ullrich, Tobias Bexte et al.|Blood|2022Cited by 22
P1354: CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.Nawid Albinger, Evelyn Ullrich, Tobias Bexte et al.|HemaSphere|2023Cited by 1